Researchers analyzed data from 4,471 US adults to explore the link between atherogenic index of plasma (AIP) and phenotypic age acceleration (PhenoAgeAccel). They uncovered a non-linear relationship with an inflection at –0.043. Additionally, insulin resistance (HOMA-IR) explains 39% of the effect, spotlighting AIP as a practical clinical marker for aging acceleration.
Key points
- AIP rise associates with significant PhenoAgeAccel increase, notably 1.82 years per unit.
- Insulin resistance (HOMA-IR) mediates 39.21% of the AIP–aging link.
- Network pharmacology reveals core aging targets (INS, APOE, APOB) and pathways (AMPK, JAK-STAT, FoxO).
Q&A
- What is AIP?
- How is PhenoAgeAccel measured?
- What does HOMA-IR mediation mean?
